 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | KIO-301 / Kiora Pharma
Trial completion date, Trial primary completion date: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (clinicaltrials.gov) - Mar 15, 2024
P1/2, N=12, Recruiting, Sponsor: Kiora Pharmaceuticals, Inc.
Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
- || KIO-301 / Kiora Pharma
Enrollment open: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (clinicaltrials.gov) - Sep 30, 2023
P1/2, N=12, Recruiting, Sponsor: Kiora Pharmaceuticals, Inc.
Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Feb 2024 --> Dec 2024 Active, not recruiting --> Recruiting
- ||| KIO-301 / Kiora Pharma
Enrollment closed, Enrollment change: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=6, Active, not recruiting, Sponsor: Kiora Pharmaceuticals, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=12 --> 6
- KIO-301 / Kiora Pharma
Intravitreal Injection of (WEST 3004) - Aug 21, 2023 - Abstract #AAO2023AAO_458;
- KIO-301 / Kiora Pharma
Trial completion date, Trial primary completion date: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (clinicaltrials.gov) - Jul 28, 2023
P1/2, N=6, Recruiting, Sponsor: Kiora Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | N=12 --> 6 Trial completion date: May 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Jan 2024
- KIO-301 / Kiora Pharma
Enrollment open, Trial initiation date: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (clinicaltrials.gov) - Dec 27, 2022
P1/2, N=6, Recruiting, Sponsor: Kiora Pharmaceuticals, Inc.
Trial completion date: May 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Jan 2024 Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Nov 2022
- | KIO-301 / Kiora Pharma
New P1/2 trial: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (clinicaltrials.gov) - Mar 16, 2022
P1/2, N=6, Not yet recruiting, Sponsor: Kiora Pharmaceuticals, Inc.